G

Galectin Therapeutics
D

GALT

2.92000
USD
-0.06
(-2.01%)
مغلق
حجم التداول
4,304
الربح لكل سهم
-1
العائد الربحي
-
P/E
-4
حجم السوق
184,811,428
أصول ذات صلة
E
EBS
-0.31500
(-4.22%)
7.15000 USD
E
EXAS
-0.280
(-0.57%)
48.500 USD
H
HAE
1.000
(1.35%)
75.240 USD
I
INO
-0.03500
(-2.33%)
1.47000 USD
NBIX
NBIX
0.580
(0.44%)
132.010 USD
S
SRPT
-0.970
(-7.53%)
11.910 USD
VRTX
VRTX
-2.89
(-0.61%)
469.58 USD
المزيد
الأخبار المقالات

العنوان: Galectin Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.